Press Releases

Date Title and Summary
Toggle Summary Isis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods
Toggle Summary Isis Pharmaceuticals Prices Offering of $425 Million of 1.00% Convertible Senior Notes
Toggle Summary Isis Pharmaceuticals Announces Proposed Offering of $425 Million of Convertible Senior Notes
Toggle Summary Isis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2014
Toggle Summary Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancement of ISIS-BIIB3 Rx
Toggle Summary Isis Pharmaceuticals Earns $7.5 Million Milestone Payment From AstraZeneca
Toggle Summary Isis Pharmaceuticals Earns $5 Million in Milestone Payment From GSK for Advancement of ISIS-GSK5 Rx
Toggle Summary Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call
Toggle Summary Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference
Toggle Summary Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Studies in Infants and Children With Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals Earns $18 Million From GSK for Advancing ISIS-TTR Rx
Toggle Summary Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress
Toggle Summary Isis Pharmaceuticals Earns $1.5 Million From GSK for the Advancement of ISIS-GSK4 Rx
Toggle Summary Isis Pharmaceuticals to Present at the Leerink Partners Rare Disease Roundtable
Toggle Summary Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin
Toggle Summary Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
Toggle Summary Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014
Toggle Summary Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-APOCIII Rx in Patients with FCS
Toggle Summary Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular Atrophy
Toggle Summary Isis Reports Financial Results and Highlights for Second Quarter 2014
Toggle Summary Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
Toggle Summary Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call
Toggle Summary Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a)
Toggle Summary Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx
Toggle Summary Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program
Toggle Summary Isis Pharmaceuticals Earns $1 Million From GSK for Advancing ISIS-TTR Rx
Toggle Summary Isis Pharmaceuticals Earns $10 Million Milestone Payment from Biogen Idec
Toggle Summary Isis Pharmaceuticals Reports Final Phase 2 Data on ISIS-GCGR RX Showing Significant Reduction in HbA1c in Patients with Type 2 Diabetes
Toggle Summary Isis Pharmaceuticals to Present at the 2014 Wells Fargo Healthcare Conference
Toggle Summary Isis Pharmaceuticals to Host Investor Event to Discuss ISIS-GCGR Rx Phase 2 Data Presented at the 2014 ADA Scientific Sessions
Toggle Summary Isis Pharmaceuticals Earns $15 Million from AstraZeneca for Initiation of Phase 1 Study of ISIS-AR Rx
Toggle Summary Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-DMPK Rx to Treat Myotonic Dystrophy Type 1
Toggle Summary Isis Pharmaceuticals to Present at the Goldman Sachs 35th Annual Global Healthcare Conference
Toggle Summary Isis Pharmaceuticals to Present a General Corporate Update at its 2014 Annual Meeting of Stockholders and Open House
Toggle Summary Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
Toggle Summary Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-PKK Rx
Toggle Summary Webcast Alert: Isis Pharmaceuticals Announces its R&D Day Presentation
Toggle Summary Isis Pharmaceuticals Earns $3.0 Million from GSK
Toggle Summary Isis Pharmaceuticals Reports Phase 2 Data on ISIS-GCGR Rx Showing Significant Reduction in HbA1c in Patients With Type 2 Diabetes
Toggle Summary Isis Pharmaceuticals to Present at the UBS Global Healthcare Conference
Toggle Summary Genzyme and Isis Receive Corporate Award from the National Organization for Rare Disorders (NORD) for the Development of KYNAMRO®
Toggle Summary Isis Pharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Toggle Summary Isis Reports Financial Results and Highlights for First Quarter 2014
Toggle Summary Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx in Patients With Familial Chylomicronemia
Toggle Summary Isis Pharmaceuticals to Present at the Deutsche Bank 39th Annual Health Care Conference
Toggle Summary Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx in Patients With High Triglycerides and Type 2 Diabetes
Toggle Summary Webcast Alert: Isis Pharmaceuticals' First Quarter 2014 Financial Results Conference Call
Toggle Summary ISIS Pharmaceuticals' and Biogen idec's innovative collaboration voted breakthrough alliance of 2014
Toggle Summary Isis Reports Updated Results from ISIS-SMN Rx Clinical Studies in Infants and Children with Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals to Host Investor Event to Discuss ISIS-SMN Rx Data Presented at the 2014 AAN Annual Meeting
Toggle Summary Isis Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference
Toggle Summary Isis Reports Final Phase 2 Data On ISIS-APOCIII Rx In Patients With High Triglycerides Taking Fibrates
Toggle Summary Isis Announces Antisense Targeting Of HBV Produces Dose-Dependent Reductions In Hepatitis B Virus In An Animal Model Of HBV
Toggle Summary Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-ANGPTL3 Rx to Treat Hyperlipidemia
Toggle Summary Isis Pharmaceuticals to Present at the Barclays Global Healthcare Conference
Toggle Summary ISIS Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx
Toggle Summary Isis Reports Financial Results And Highlights For 2013
Toggle Summary Isis Pharmaceuticals to Present at the Cowen 34th Annual Health Care Conference
Toggle Summary Isis Pharmaceuticals Reports Interim Results from ISIS-SMN Rx Phase 2 Study in Infants with Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals Reports Interim Results from ISIS-SMN Rx Multiple Dose Study in Children with Spinal Muscular Atrophy
Toggle Summary Webcast Alert: Isis Pharmaceuticals' 2013 Financial Results and Highlights Conference Call
Toggle Summary Isis Pharmaceuticals to Present at the 2014 RBC Capital Markets Global Healthcare Conference
Toggle Summary Isis Announces Positive Opinion on European Orphan Drug Designation for ISIS-TTR Rx
Toggle Summary Isis Pharmaceuticals Advances ISIS-SMN Rx in Infants and Children with Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals to Present at the Leerink Global Healthcare Conference
Toggle Summary Joseph Loscalzo, M.D., Ph.D., Joins Isis Pharmaceuticals' Board of Directors
Toggle Summary Isis Pharmaceuticals to Receive $7.5 Million From Alnylam
Toggle Summary Isis Announces Positive Decision on European Orphan Drug Designation for ISIS-APOCIII Rx
Toggle Summary Isis Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Toggle Summary Isis Pharmaceuticals to Present at the Oppenheimer 24th Annual Healthcare Conference
Toggle Summary Isis Pharmaceuticals Earns $2 Million from GSK for the Advancement of ISIS-TTR Rx
Toggle Summary Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-GSK3 Rx and Earns $3 Million Milestone Payment From GSK
Toggle Summary Isis Pharmaceuticals to Present at the 2013 Deutsche Bank BioFEST
Toggle Summary Isis Pharmaceuticals to Investigate a Higher Dose of ISIS-SMN Rx in Children with Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals Reports Fifth Positive Phase 2 Data Set for ISIS-APOCIII Rx Showing Significant Reductions in Triglyceride and ApoC-III Levels
Toggle Summary Isis Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-APO(a) Rx Produces Significant Reductions in Lp(a) Levels
Toggle Summary Isis Earns $5 Million in Milestone Payment from GSK for Advancement of ISIS-GSK4 Rx
Toggle Summary Isis Pharmaceuticals Earns $1.5M from the Advancement of the Phase 2 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
Toggle Summary Isis Reports Financial Results and Highlights for Third Quarter 2013
Toggle Summary Webcast Alert: Isis Pharmaceuticals' Third Quarter 2013 Financial Results Conference Call
Toggle Summary Isis Earns $10 Million Milestone Payment from Biogen Idec for Advancement of ISIS-DMPK Rx to Treat Myotonic Dystrophy
Toggle Summary Isis Pharmaceuticals' Stanley Crooke Awarded 2013 Distinguished Scientist
Toggle Summary Isis Earns $7 Million in Milestone Payments from GSK for Advancement of ISIS-GSK3 Rx to Treat Viral Infection
Toggle Summary Isis Pharmaceuticals Advances Phase 2 Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals to Present at the Leerink Swann Rare Disease Roundtable
Toggle Summary Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients With Familial Chylomicronemia
Toggle Summary Isis Reports Follow-Up Data From ISIS-SMN Rx Phase 1 Study in Children With Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals' Stanley Crooke Awarded Corporate Forum's Director of the Year
Toggle Summary Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders
Toggle Summary Isis Pharmaceuticals to Present at the 2013 Stifel Healthcare Conference
Toggle Summary Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
Toggle Summary Isis Reports Interim Phase 2 Data on ISIS-APOCIII Rx as a Single Agent in Patients With Very High to Severely High Triglycerides
Toggle Summary Isis Pharmaceuticals to Present at the Canaccord Genuity 33rd Annual Growth Conference
Toggle Summary Isis Reports Financial Results and Highlights for Second Quarter 2013
Toggle Summary Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients With Rheumatoid Arthritis
Toggle Summary Isis Pharmaceuticals Earns $2 Million From GSK for the Advancement of ISIS-TTR Rx
Toggle Summary Webcast Alert: Isis Pharmaceuticals' Second Quarter 2013 Financial Results Conference Call
Toggle Summary Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Significant Reductions of ApoC-III and Triglycerides in Patients With High Triglycerides Taking Fibrates
Toggle Summary Isis Pharmaceuticals to Present at the 8th Annual JMP Securities Healthcare Conference